deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01662895

High-Dose Deferoxamine in Intracerebral Hemorrhage (HI-DEF)

Futility Study of Deferoxamine in Intracerebral Hemorrhage

Sponsor: Beth Israel Deaconess Medical Center

Updated 14 times since 2017 Last updated: May 29, 2019 Started: Mar 18, 2013 Primary completion: Jan 15, 2014 Completion: May 10, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol \[NCT02175225

Other Intracerebral Hemorrhage trials with similar outcome

Browse all Intracerebral Hemorrhage trials

A PHASE2 clinical study on Intracerebral Hemorrhage, this trial is terminated or withdrawn. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 14 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2020 · 14 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Mar 2022 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

Show 9 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Sep 2019 — Nov 2020 [monthly]

    Terminated PHASE2

  3. Jun 2019 — Sep 2019 [monthly]

    Terminated PHASE2

    Status: SuspendedTerminated

  4. Feb 2019 — Jun 2019 [monthly]

    Suspended PHASE2

  5. Jan 2019 — Feb 2019 [monthly]

    Suspended PHASE2

  6. Jun 2018 — Jan 2019 [monthly]

    Suspended PHASE2

  7. Oct 2017 — Jun 2018 [monthly]

    Suspended PHASE2

  8. Feb 2017 — Oct 2017 [monthly]

    Suspended PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Suspended PHASE2

    First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Dalhousie University
  • Duke University
  • Hartford Hospital
  • Henry Ford Hospital
  • Hopital de l'Enfant-Jesus
  • Johns Hopkins University
  • Massachusetts General Hospital
  • Medical University of South Carolina
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Ohio State University
  • Oregon Health and Science University
  • Rhode Island Hospital
  • St. Joseph's Hospital and Medical Center, Phoenix
  • Stanford University
  • The Cleveland Clinic
  • The University of Texas Health Science Center, Houston
  • Tufts Medical Center
  • University of Alberta
  • University of Calgary
  • University of California, San Francisco
  • University of Florida
  • University of Iowa
  • University of Maryland
  • University of Massachusetts, Worcester
  • University of North Carolina
  • University of Pennsylvania
  • University of Virginia
  • University of Washington
  • Yale New Haven Hospital
Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .